Medicine
Motpoly XR 100 mg extended-release capsule
Motpoly XR 100 mg extended-release capsule is a prescription medicine containing Lacosamide for oral use, marketed by Aucta Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to…
Key facts
- Active ingredient (INN)
- Lacosamide
- Brand
- Motpoly XR
- Strength
- 100 mg
- Dosage form
- Extended-release capsule
- Route
- Oral
- Packs
- 60 capsules
- Marketing authorisation holder
- Aucta Pharmaceuticals
- Manufacturer
- Aucta Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Schedule CV
- ATC code
- N03AX18 Lacosamide
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 5 May 2023
- Identifiers
- RxCUI 2637018, 2637025, 2637027 +3DailyMed set ID fb8235b4-4cd3-6f22-e053-6294a90a545cNDC 73289-0063Application NDA216185
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 60 capsule, extended release in 1 bottle, plastic | 73289-0063-2 | Aucta Pharmaceuticals | 5 May 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Lacosamide
Clinical summary
Lacosamide is a prescription medicine indicated for treatment of partial-onset seizures in patients 1 month of age and older, among other approved uses. It is available as tablets, oral solution and injection for intravenous use. MedsAcross supplies Lacosamide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about LacosamideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Vimpat prescribing information (UCB) · U.S. National Library of Medicine, DailyMed
- Lacosamide UCB: European public assessment report (EPAR) · European Medicines Agency
- Vimpat: European public assessment report (EPAR) · European Medicines Agency
Need Motpoly XR 100 mg extended-release capsule for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.